TITLE

Antibody-Mediated Activation of FGFR1 Induces FGF23 Production and Hypophosphatemia

AUTHOR(S)
Wu, Ai-Luen; Feng, Bo; Chen, Mark Z.; Kolumam, Ganesh; Zavala-Solorio, Jose; Wyatt, Shelby K.; Gandham, Vineela D.; Carano, Richard A. D.; Sonoda, Junichiro
PUB. DATE
February 2013
SOURCE
PLoS ONE;Feb2013, Vol. 8 Issue 2, p1
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The phosphaturic hormone Fibroblast Growth Factor 23 (FGF23) controls phosphate homeostasis by regulating renal expression of sodium-dependent phosphate co-transporters and cytochrome P450 enzymes involved in vitamin D catabolism. Multiple FGF Receptors (FGFRs) can act as receptors for FGF23 when bound by the co-receptor Klotho expressed in the renal tubular epithelium. FGFRs also regulate skeletal FGF23 secretion; ectopic FGFR activation is implicated in genetic conditions associated with FGF23 overproduction and hypophosphatemia. The identity of FGFRs that mediate the activity of FGF23 or that regulate skeletal FGF23 secretion remains ill defined. Here we report that pharmacological activation of FGFR1 with monoclonal anti-FGFR1 antibodies (R1MAb) in adult mice is sufficient to cause an elevation in serum FGF23 and mild hypophosphatemia. In cultured rat calvariae osteoblasts, R1MAb induces FGF23 mRNA expression and FGF23 protein secretion into the culture medium. In a cultured kidney epithelial cell line, R1MAb acts as a functional FGF23 mimetic and activates the FGF23 program. siRNA-mediated Fgfr1 knockdown induced the opposite effects. Taken together, our work reveals the central role of FGFR1 in the regulation of FGF23 production and signal transduction, and has implications in the pathogenesis of FGF23-related hypophosphatemic disorders.
ACCESSION #
87625374

 

Related Articles

  • Circulating aKlotho influences phosphate handling by controlling FGF23 production. Smith, Rosamund C.; O'Bryan, Linda M.; bFarrow, Emily G.; Summers, Lelia J.; Clinkenbeard, Erica L.; Roberts, Jessica L.; Cass, Taryn A.; Saha, Joy; Broderick, Carol; Linda Ma, Y.; Qing Qiang Zeng; Kharitonenkov, Alexei; Wilson, Jonathan M.; Qianxu Guo; Haijun Sun; Allen, Matthew R.; Burr, David B.; Breyer, Matthew D.; White, Kenneth E. // Journal of Clinical Investigation;Dec2012, Vol. 122 Issue 12, p4710 

    The FGF23 coreceptor aKlotho (aKL) is expressed as a membrane-bound protein (mKL) that forms heteromeric complexes with FGF receptors (FGFRs) to initiate intracellular signaling. It also circulates as an endoproteolytic cleavage product of mKL (cKL). Previously, a patient with increased plasma...

  • Selection of a novel FGF23-binding peptide antagonizing the inhibitory effect of FGF23 on phosphate uptake. Huang, Tao; Lin, Xiaomian; Li, Quchou; Luo, Wu; Song, Li; Tan, Xiangpeng; Wang, Wenhui; Li, Xiaokun; Wu, Xiaoping // Applied Microbiology & Biotechnology;Apr2015, Vol. 99 Issue 7, p3169 

    Fibroblast growth factor 23 (FGF23) is a bone-derived endocrine regulator of phosphate homeostasis and has been considered as a potential therapeutic target for hypophosphatemic disorders. Herein, we isolated a novel FGF23-binding peptide by screening a phage display library with FGF23, the...

  • The Chemical Defensive System in the Pathobiology of Idiopathic Environment-Associated Diseases. Korkina, L.; Scordo, M. G.; Deeva, I.; Cesareo, E.; De Luca, C. // Current Drug Metabolism;Oct2009, Vol. 10 Issue 8, p914 

    Chemical defensive system consisting of bio-sensoring, transmitting, and responsive elements has been evolved to protect multi-cellular organisms against environmental chemical insults (xenobiotics) and to maintain homeostasis of endogenous low molecular weight metabolites (endobiotics). Both...

  • Intrinsic Hepatic Phenotype Associated with the Cyp1a2 Gene as Shown by cDNA Expression Microarray Analysis of the Knockout Mouse. Smith, Andrew G.; Davies, Reginald; Dalton, Timothy P.; Miller, Marian L.; Judah, David; Riley, Joan; Gant, Timothy; Nebert, Daniel W. // Environmental Health Perspectives;May2003 Toxicogenomics, Vol. 111 Issue 6, p855 

    Several forms of cytochrome P450 (CYP) appear to metabolize principally pharmaceutical agents, as well as other dietary and plant chemicals. Other CYP forms have major roles in steroid, sterol, and bile acid metabolism. CYP1A2 expression is constitutively high in mouse liver and is well known...

  • FIBROBLAST GROWTH FACTOR-23 AND HYPOPHOSPHATEMIA IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE PATIENTS.  // Journal of Medical Biochemistry;Mar2012, Vol. 31 Issue 1, p12 

    The article presents a study which examined the fibroblast growth factor 23 and hypophosphatemia in patients with chronic obstructive pulmonary disease (COPD). The researchers evaluated blood samples and serum phosphate levels in a panel of routine laboratory tests. The study found elevated...

  • Novel Cyclic Phosphate Prodrug Approach for Cytochrome P450-activated Drugs Containing an Alcohol Functionality. Kristiina Huttunen; Niina Mähönen; Jukka Leppänen; Jouko Vepsäläinen; Risto Juvonen; Hannu Raunio; Hanna Kumpulainen; Tomi Järvinen; Jarkko Rautio // Pharmaceutical Research;Apr2007, Vol. 24 Issue 4, p679 

    AbstractPurpose??A cyclic phosphate prodrug of a descriptive molecule containing an alcohol functionality was designed, synthesized and characterizedin vitroas a cytochrome P450 (CYP) -selective prodrug.Materials and Methods??To achieve efficient CYP-oxidation and prodrug bioconversion,...

  • Fibroblast growth factor 23: the making of a hormone. Schiavi, S. C. // Kidney International;Feb2006, Vol. 69 Issue 3, p425 

    Fibroblast growth factor 23 (FGF23) modulates serum phosphate and 1α,25-dihydroxyvitamin D3 levels. FGF23 expression is in turn regulated by 1α,25-dihydroxyvitamin D3 and dietary phosphate load, and is strikingly elevated during renal progression. In this issue, Nagano and colleagues...

  • Oncogenic osteomalacia illustrating the effect of fibroblast growth factor 23 on phosphate homeostasis. Westerberg, Per-Anton; Linde, Torbjörn; Vanderschueren, Dirk; Billen, Jaak; Jans, Ivo; Ljunggren, Östen // Nephrology Dialysis Transplantation;Jun2012, Vol. 5 Issue 3, p240 

    In oncogenic osteomalacia (OOM), fibroblast growth factor 23 (FGF23) induces renal phosphate wasting and inhibits the appropriate increase of calcitriol. A patient suffering from OOM is described. Serum calcium, phosphate, biointact parathyroid hormone and intact FGF23 as well as the calcitriol...

  • Klotho: FGF23 coreceptor and FGF23-regulating hormone. Jüppner, Harald; Wolf, Myles // Journal of Clinical Investigation;Dec2012, Vol. 122 Issue 12, p4336 

    Low levels of phosphate can disrupt bone ossification and predispose to fractures. FGF23 is one of the major determinants of phosphate homeostasis, acting to increase urinary phosphate excretion. However, the regulation of FGF23 is incompletely understood. In this issue of the JCI, Smith et al....

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics